Publication:
How removing prescription drugs from reimbursement lists increases the pharmaceutical expenditures for alternatives

dc.contributor.departmentDepartment of Business Administration
dc.contributor.departmentN/A
dc.contributor.kuauthorAli, Özden Gür
dc.contributor.kuauthorTopaler, Başak
dc.contributor.kuprofileFaculty Member
dc.contributor.kuprofileMaster Student
dc.contributor.otherDepartment of Business Administration
dc.contributor.schoolcollegeinstituteCollege of Administrative Sciences and Economics
dc.contributor.schoolcollegeinstituteGraduate School of Business
dc.contributor.yokid57780
dc.contributor.yokidN/A
dc.date.accessioned2024-11-10T00:02:46Z
dc.date.issued2011
dc.description.abstractChanging the status of drugs from prescription-only to over-the-counter and removing them from reimbursement list has been used as a cost reduction measure by several third-party payers. in June 2006, the Turkish government, in an effort to curtail costs, removed many prescription drugs from the reimbursement list. This paper examines the effect of this policy on the expenditures for drugs that were removed from the reimbursement list and for their reimbursable alternatives that can be prescribed by physicians on patient request. To accomplish these goals, Actual expenditures in four anatomical therapeutic chemical (ATC) groups were compared with expected expenditures in the absence of policy change for both removed and alternative drugs. the findings indicated that the expenditures on alternative drugs beyond expectations. in two of the four ATC groups involved in the study, the increase was large enough to wipe out the reduction in expenditures on the drugs removed from the reimbursement list.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue6
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.volume12
dc.identifier.doi10.1007/s10198-010-0270-2
dc.identifier.eissn1618-7601
dc.identifier.issn1618-7598
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-80455168517
dc.identifier.urihttp://dx.doi.org/10.1007/s10198-010-0270-2
dc.identifier.urihttps://hdl.handle.net/20.500.14288/16196
dc.identifier.wos298758300007
dc.keywordsPharmaceutical expenditures
dc.keywordsReimbursement
dc.keywordsHealth policy
dc.keywordsCost-effectiveness
dc.keywordsSubstitution with alternatives
dc.languageEnglish
dc.publisherSpringer
dc.sourceEuropean Journal of Health Economics
dc.subjectEconomics
dc.subjectHealth policy services
dc.titleHow removing prescription drugs from reimbursement lists increases the pharmaceutical expenditures for alternatives
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authorid0000-0002-9409-4532
local.contributor.authorid0000-0002-4553-0131
local.contributor.kuauthorAli, Özden Gür
local.contributor.kuauthorTopaler, Başak
relation.isOrgUnitOfPublicationca286af4-45fd-463c-a264-5b47d5caf520
relation.isOrgUnitOfPublication.latestForDiscoveryca286af4-45fd-463c-a264-5b47d5caf520

Files